Various types of cancers (Kitamura and Motohashi, 2018) are characterized by chronic activation of the cytoprotective NRF2 system which accounts, at least partially, for the selection of more aggressive neoplastic phenotypes by conferring survival and growth advantage, as well as resistance to therapy (Cuadrado et al., 2018). Here, NFE2L2 is linked to cancer.